Randomized Trial of 24 or 48 Weeks of Peginterferon Alfa-2a Plus Ribavirin for HCV Genotype 1-infected Patients
Status:
Completed
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
Chronic hepatitis C virus (HCV) infection is prevalent in the world, affecting 3% of the
world's population. The current standard of therapy is pegylated interferon and ribavirin,
reaching 54-63% of successful rates. In patients with HCV genotype 1 infection, a 48 week
course of combination therapy has achieved a higher successful rate that a 24 weeks course of
therapy. However, several studies in Taiwan have shown that a 24 week course of therapy has
comparable or even better response to a 48 week course of therapy in Western countries.
Therefore, whether a 48 week course of therapy can achieve a higher response to a 24 week
course of therapy in Taiwanese patients with genotype 1 HCV infection remains unclear.